source
- Superluminal Medicines raises $60M Series B to launch Phase 1 trial of genetic obesity therapySuperluminal Medicines, a Boston‑based biotech, announced it has closed a $60 million Series B financing round. The capital will fund the company’s first‑in‑human study of its genetic obesity candi…
- Overdose deaths fall sharply in US and abroad, report links decline to naloxone and harm-reduction measuresA new report highlights a sudden drop in drug overdose deaths after years of consistently high numbers in the United States. The data show that U.S. deaths fell 27% in 2024 and preliminary figures…